Follow Forum_Psych on Twitter
Search
 
 

Display results as :
 


Rechercher Advanced Search

Statistics
We have 222 registered users
The newest registered user is raheelmemon

Our users have posted a total of 1140 messages in 613 subjects
If you are seeing this, you have attempted to link to the UpToDate widget but are experiencing a problem. Please visit UpToDate for more information.
Share

Bipolar I Psycho-Pharm Quiz

View previous topic View next topic Go down

Bipolar I Psycho-Pharm Quiz

Post  Admin on Sat Jul 27, 2013 1:27 pm

.
Q: Which of the following medication is NOT indicated for maintenance treatment of Bipolar I ?

(a) Aripiprazole tabs
(b) Olanzapine tabs
(c) Quetiapine tabs
(d) Risperidone tabs
(e) Ziprasidone tabs


*****************
Click on to post your comments
avatar
Admin
Admin
Admin

Posts : 948
Points : 2102
Reputation : 0
Join date : 2011-02-19
Location : Philadelphia

http://psychiatry.find-forum.net

Back to top Go down

Re: Bipolar I Psycho-Pharm Quiz

Post  Admin on Sat Jul 27, 2013 9:20 pm

Admin wrote:.
Q: Which of the following medication is NOT indicated for maintenance treatment of Bipolar I ?

(a) Aripiprazole tabs
(b) Olanzapine tabs
(c) Quetiapine tabs
(d) Risperidone tabs
(e) Ziprasidone tabs


Answer: (d) Risperidone tabs.

The first line medications consistently supported across multiple randomized trials for maintenance of bipolar disorder are:
(a) Lithium (more effective in preventing manic recurrences)
(b) Lamotrigine (more effective in delaying or preventing depression than manic or mixed episodes)
(c) Risperidone intramuscular injection (for nonadherent patients)- Most trials done on long acting IM form of risperidone, but no trial was done on oral formulation of risperidone (more efficacious in delaying or preventing mania than major depression)
Source:
- Deeks ED et al, Drugs. 2010;70(8 ):1001.
- Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Quiroz JA et al, Biol Psychiatry. 2010;68(2):156.

The second line medications include:
(a) Aripiprazole:
Proven efficacy for acute mania and the prevention of mania, but the evidence available thus far does not support the efficacy of aripiprazole for the treatment of acute bipolar depression and prevention of depressive relapse.
Negative findings for aripiprazole in the treatment of acute bipolar depression have been attributed to high study doses, rapid titration, and high placebo rates.
Source: A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder. Yatham LN, J Affect Disord. 2011;128 Suppl 1:S21.

In 2011 Aripiprazole received FDA approval as an adjunct to the mood stabilizers lithium or valproate for the maintenance treatment of Bipolar I Disorder.

(b) Divalproex

(c) Quetiapine:
In 2008 FDA approved Quetiapine for the maintenance treatment of patients with bipolar I disorder, as adjunct to lithium or divalproex.
The FDA approval was based on 2 multicentre, randomised, double-blind, placebo-controlled clinical trials which are part of the clinical trial program known as BOLDER (Bipolar Depression). Pooled study results indicated that patients treated with Quetiapine plus Lithium or Divalproex had a risk reduction of 70% relative to those in the placebo arm for time to recurrence of a mood event. This reduction in risk was significant for both recurrence of manic episodes and recurrence of depressive episodes.

(d) Olanzapine: second line for risk of metabolic side effects.
Olanzapine appeared to delay or prevent mania more effectively than major depression.
Source: Olanzapine in long-term treatment for bipolar disorder. Cipriani A et al. Cochrane Database Syst Rev. 2009.
Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis. Cipriani A et al. Psychopharmacol. 2010;24(12):1729.
in 2004 FDA approved Olanzapine for maintenance treatment of bipolar disorder.

(e) Ziprasidone:
In 2009 FDA approved Ziprasidone as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder in adults.
Approval of the indication was based on data from a double-blind, placebo-controlled trial of 240 stabilized patients showing that the addition of ziprasidone to mood stabilizers significantly delayed time to recurrence of a mood episode.


Please add your comments below. Thanks

*****************
Click on to post your comments
avatar
Admin
Admin
Admin

Posts : 948
Points : 2102
Reputation : 0
Join date : 2011-02-19
Location : Philadelphia

http://psychiatry.find-forum.net

Back to top Go down

hello

Post  koustubh.bagul on Sat Jul 27, 2013 9:31 pm

all atypical anti psychotics  could be used, olanzapine, qutiapin, aripiprazol, resperidon, ziprasidon. but in clinical practices less of resperidon. may be its odd man out!

koustubh.bagul

Posts : 7
Points : 7
Reputation : 0
Join date : 2012-08-21
Age : 33
Location : AMRAVATI MAHARASHTRA INDIA

Back to top Go down

Re: Bipolar I Psycho-Pharm Quiz

Post  Admin on Sat Jul 27, 2013 9:33 pm

koustubh.bagul wrote:all atypical anti psychotics  could be used, olanzapine, qutiapin, aripiprazol, resperidon, ziprasidon. but in clinical practices less of resperidon. may be its odd man out!

Yes Koustubh.bagul. we can use all atypical antipsychotics. FDA had not approved Risperidone oral formulation, because no studies available.
Goodluck 

*****************
Click on to post your comments
avatar
Admin
Admin
Admin

Posts : 948
Points : 2102
Reputation : 0
Join date : 2011-02-19
Location : Philadelphia

http://psychiatry.find-forum.net

Back to top Go down

Re: Bipolar I Psycho-Pharm Quiz

Post  Sponsored content


Sponsored content


Back to top Go down

View previous topic View next topic Back to top

- Similar topics

 
Permissions in this forum:
You cannot reply to topics in this forum